Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non--small-cell lung cancer.

@article{Kanemoto2014OutcomesAP,
  title={Outcomes and prognostic factors for recurrence after high-dose proton beam therapy for centrally and peripherally located stage I non--small-cell lung cancer.},
  author={Ayae Kanemoto and T. Okumura and H. Ishikawa and M. Mizumoto and Y. Oshiro and K. Kurishima and S. Homma and T. Hashimoto and A. Ohkawa and Haruko Numajiri and T. Ohno and T. Moritake and K. Tsuboi and T. Sakae and H. Sakurai},
  journal={Clinical lung cancer},
  year={2014},
  volume={15 2},
  pages={
          e7-12
        }
}
INTRODUCTION This study was conducted to determine disease control rates and prognostic factors associated with recurrence of centrally and peripherally located stage I NSCLC treated using high-dose PBT. PATIENTS AND METHODS Seventy-four patients with 80 centrally or peripherally located stage I NSCLCs were treated with PBT. A protocol using 72.6 Gy (RBE) in 22 fractions was used for centrally located tumors, and 66 Gy (RBE) in 10 or 12 fractions was used for peripherally located tumors. Data… Expand
Ablative dose proton beam therapy for stage I and recurrent non-small cell lung carcinomas
TLDR
Ablative dose hypofractionated PBT was safe and promising for stage I and recurrent NSCLC and no grade 3 or 4 treatment-related toxicities developed. Expand
Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer
TLDR
IGPT appears to be effective and well tolerated for all patients with stage I NSCLC and Common Toxicity Criteria for Adverse Events (v.4.0). Expand
Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.
  • Q. Nguyen, N. Ly, +9 authors J. Cox
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2015
TLDR
This report of outcomes after proton therapy for 134 patients indicated that this regimen produced excellent OS with tolerable toxicity. Expand
Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.
TLDR
PBT appears to yield acceptable survival rates, with a low rate of toxicities, in patients with Stage I non-small cell lung cancer according to the 7th edition of UICC. Expand
Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.
TLDR
According to the long-term follow-up data, proton therapy with ablative doses is well tolerated and effective in medically inoperable early-stage NSCLC and systemic therapy should be considered to reduce the rate of distant metastasis in cases of T2 and T3 lesions. Expand
Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.
TLDR
Although hypo-fractionated PBT may lead to additional clinical benefit when compared with photon SBRT, no statistically significant survival benefit was observed in the treatment of ES NSCLC in this hypothesis-generating meta-analysis after adjusting for potential confounding variables. Expand
Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
TLDR
This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions. Expand
Verification of Dose Distribution in Carbon Ion Radiation Therapy for Stage I Lung Cancer.
TLDR
According to this simulation analysis of C-ion RT for stage I NSCLC, a few fields were reported as unacceptable and required resetting of body position and reconfirmation, and tumor displacement and change in water-equivalent pathlength were identified as factors influencing the robustness of dose distribution. Expand
[Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer].
TLDR
The definition, indication, dose regimens, dose-volume constraints for organs at risk, radiation technology, treatment side effect of centrally located NSCLC treated with SBRT and stereotactic body proton therapy are reviewed. Expand
Dose assessment for patients with stage I non-small cell lung cancer receiving passive scattering carbon-ion radiotherapy using daily computed tomographic images: A prospective study.
  • Y. Li, Y. Kubota, +10 authors T. Ohno
  • Medicine
  • Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2020
TLDR
This study establishes that CT image-based TM is robust compared with conventional BM for both daily and accumulated dose distributions, and daily CT alignment is recommended for patients with stage I NSCLC receiving C-ion RT. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 35 REFERENCES
High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center.
TLDR
High-dose hypofractionated proton therapy achieves excellent outcomes for lung carcinomas that are peripherally or centrally located, suggesting that better results could be seen with intensified treatment. Expand
Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba.
TLDR
Proton beam therapy was effective and well tolerated in medically inoperable patients with Stage I NSCLC, and there was no statistically significant difference in progression-free rate between T1 and T2 tumors. Expand
Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
TLDR
Hypofractionated high-dose proton beam therapy seems feasible and effective for Stage I NSCLC, and proton beams may contribute to enhanced efficacy and lower toxicity in the treatment of patients with Stage INSCLC. Expand
Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.
TLDR
SRT is well tolerated in patients with extensive comorbidity with high local control rates and minimal toxicity, and such risk-adapted SRT schedules should be considered treatment of choice in patients presenting with medically inoperable Stage I NSCLC. Expand
Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
TLDR
Late recurrences after SABR are infrequent and two distinct patterns account for most cases; the predominant pattern is out-of-field, isolated distant recurrence presenting early, despite initial PET staging. Expand
Clinical evaluation of proton radiotherapy for non-small-cell lung cancer.
TLDR
Proton therapy is a very safe and effective treatment for patients with NSCLC, especially for those with early stages, and the relative merit of proton therapy in comparison with stereotactic photon radiotherapy or three-dimensional conformal photons radiotherapy remains to be defined through future clinical trials. Expand
Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial.
TLDR
In this series, SBRT was well tolerated and confirmed its efficacy, with local control and survival rates globally superior to those reported using conventional radiotherapy. Expand
High-dose proton beam therapy for Stage I non-small-cell lung cancer.
TLDR
Proton beam therapy is a promising treatment modality for Stage I NSCLC, though locoregional relapse and late pulmonary toxicities in Stage IB patients were substantial, and further investigation of PBT for stages I and II is warranted. Expand
Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
TLDR
Stereotactic body radiation therapy for T2 non-small-cell lung cancer has a higher local recurrence rate and trended toward a worse survival than did T1 lesions, and tumor size is an important predictor of response to stereotacticBody radiation therapy and should be considered in treatment planning. Expand
Hypofractionated proton beam radiotherapy for stage I lung cancer.
TLDR
High-dose hypofractionated proton beam radiotherapy can be administered safely, with minimal toxicity, to patients with stage I lung cancer, and local tumor control appears to be improved when compared to historical results utilizing conventional radiotherapy. Expand
...
1
2
3
4
...